# Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

> **NCT00528983** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 133 (actual)

## Conditions studied

- Myelodysplastic Syndromes (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** Subcutaneous (SC) Azacitidine
- **DRUG:** Oral Azacitidine
- **DRUG:** Oral Azacitidine

## Key facts

- **NCT ID:** NCT00528983
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-11
- **Primary completion:** 2013-07-31
- **Final completion:** 2016-04-05
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528983, "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00528983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*